Owkin的K Pro AI 联合试点使用安全自然语言分析 将药物发现时间减少70% 试验长度减少35% Owkin's K Pro AI co-pilot cuts drug discovery time by 70% and trial lengths by 35% using secure, natural language analysis.

Owkin发起了K Pro,这是生物制药业的人工智能代理联合试点,目的是通过自然语言查询加快药物发现和发展。 Owkin has launched K Pro, an agentic AI co-pilot for the biopharma industry, designed to accelerate drug discovery and development through natural language queries. K Pro建在 " Owkin Zero " 上,这是一个大型生物语言模型,与包括MOSAIC数据集在内的高质量多式联运数据相结合,能够对专利数据进行安全分析。 Built on Owkin Zero, a biological large language model, and integrated with high-quality multimodal data including the MOSAIC dataset, K Pro enables secure analysis of proprietary data. 它将目标识别时间减少了70%,将临床试验时间缩短了35%,并在几天内产生了经同行审查的科学内容。 It has reduced target identification time by 70%, shortened clinical trial durations by up to 35%, and generated peer-reviewed scientific content in days. 该平台经主要制药伙伴验证后,支持早期发现、试验优化和投资者战略制定,调查数据显示数据整合和决策是最高AI值领域。 Validated with major pharmaceutical partners, the platform supports early discovery, trial optimization, and investor strategy development, with survey data showing data integration and decision-making as top AI value areas.